Phytohealth Corporation · TWSE:4108
Phytohealth — Investor Presentation (2026)
22 slides from Phytohealth's investor presentation, Oct 21, 2026
Slide 1: 2026 Investor Presentation
PhytoHealth Corporation Stock Code: 4108 2026 Investor Presentation Presented by I-Ling Lee, President Established: 1998 Listed on the Taiwan Stock Exchange: 2008 Paid-in Capital: NT$1.986 billion Chairperson: I-Li Lee PhytoHealth Corporation 1
Slide 2: Disclaimer
Disclaimer 1. Except for historical information, statements in this presentation that express forward-looking views are subject to significant risks and uncertainties, which may cause actual results to differ from those expressed. 2. The outlook presented herein reflects the Company’s current views
Slide 3: Agenda
Agenda 01 Company Overview 02 Key Developments in 2025–2026 03 Financial Information PhytoHealth Corporation 3
Slide 4: Company Overview
Company Overview Caring for Health. With Exceptional Dedication. PhytoHealth Corporation 4
Slide 5: Science-based botanical drug development
Science-based botanical drug development PhytoHealth applies Western scientific validation to medicinal botanicals used in Chinese communities for thousands of years. We develop botanical drugs that meet conventional pharmaceutical standards to address unmet clinical needs. PhytoHealth Corporation 5
Slide 6: Milestones: A Clear Vision and Steady Progress
Milestones: A Clear Vision and Steady Progress 1998 Company established. 2002 Became the first new drug R&D company recommended by the Ministry of Economic Affairs for OTC listing as a technology stock. 2008 Became the first new drug R&D company to transfer from the OTC market to the TWSE under the
Slide 7: Achievements in New Drug Development
Achievements in New Drug Development Regulatory Recognition Clinical Validation Market Acceptance • PG2® received the first new • 30 PG2® research publications • PG2® was the first botanical drug approval issued by in top-quartile leading medical new drug covered by NHI Taiwan’s TFDA (April 2010). a
Slide 8: A Proven Botanical Drug Commercialization Model
A Proven Botanical Drug Commercialization Model PhytoHealth Corporation 8
Slide 9: Three Growth Engines for the Next Five Years
Three Growth Engines for the Next Five Years 1 Core Growth 2 Global Expansion 3 Long-term Diversification PG2® Oraphine® Botanical Supplements NHI reimbursement The world’s only oral Premium healthy-aging market formulation Steady growth in self-pay sales Ingredient partnerships with Licensing in Eu
Slide 10: Key Developments in 2025–2026
Key Developments in 2025–2026 Caring for Health. With Exceptional Dedication. PhytoHealth Corporation 10
Slide 11: PG2®: 15 Years Since Launch
1 PG2®: 15 Years Since Launch From Cancer-related Fatigue Relief to Survival Outcomes Establishing Standard-of-Care Combination Therapy in Oncology PhytoHealth Corporation 11
Slide 12: Advancing Oraphine® in Domestic and International Postoperative Pain Markets
2 Advancing Oraphine® in Domestic and International Postoperative Pain Markets PhytoHealth Corporation 12
Slide 13: Oraphine®: Redefining the Gold Standard in Acute Pain
Oraphine®: Redefining the Gold Standard in Acute Pain Low addiction risk Injectable nalbuphine Oraphine® Injection Oral Administration convenience → • The world’s only oral nalbuphine Conventional opioids analgesic • For moderate to severe acute pain; adopted by multiple medical centers High addicti
Slide 14: Oraphine®: An Oral Opioid for Multimodal Postoperative Analgesia
Oraphine®: An Oral Opioid for Multimodal Postoperative Analgesia Target self-pay postoperative pain market Obstetrics and gynecology, orthopedics, neurosurgery and general surgery. Expand hospital adoption in Taiwan Adopted by nearly 40 hospitals, including Hualien Tzu Chi Hospital, Tri-Service Gene
Slide 15: Initiating Product Registration in Germany
Initiating Product Registration in Germany Aristo Pharma Manufacturing sites 5+ Annual revenue (US$ million) 500+ Employees 1,780+ Countries served 38+ Progress with Aristo Pharma Q1 2025: Signed a letter of intent for sales cooperation. Q4 2025: Initiated regulatory consultation for German Germany’
Slide 16: Bringing Our Drug R&D Expertise to Health Supplements
3 Bringing Our Drug R&D Expertise to Health Supplements PhytoHealth Corporation 16
Slide 17: Applying Patented Botanical Extraction to Functional Foods
Applying Patented Botanical Extraction to Functional Foods Astragalus Polysaccharides 3.0 rAPP® Astragalus Polysaccharides Enhanced performance High-efficacy variety / Drug-development technology applied to food Astragalus Extract 2.0 Unknown variety / Cell walls disrupted; unpurified Astragalus Sli
Slide 18: Expanding Advanced Ingredients and Commercial Partnerships
Expanding Advanced Ingredients and Commercial Partnerships Proprietary Functional Domestic & Global Consumer Health Ingredients Partnerships Applications Focus on advanced R&D supported Actively discussing functional Capture global demand for healthy by clinical evidence. ingredient partnerships wit
Slide 19: Financial Information
Financial Information Caring for Health. With Exceptional Dedication. PhytoHealth Corporation 19
Slide 20: Condensed Balance Sheet
Condensed Balance Sheet Sound financial position: ample cash and low leverage Unit: NT$ thousands Item Jun 30, 2026 % Dec 31, 2025 % Current assets 1,179,387 48 1,263,922 53 Non-current assets 1,232,191 52 1,089,155 47 Total assets 2,411,578 100 2,353,077 100 Current liabilities 40,436 2 46,119 1 No
Slide 21: Condensed Statement of Comprehensive Income
Condensed Statement of Comprehensive Income Revenue up 14% YoY; loss down 41%. Working toward profitability over the next two years. Unit: NT$ thousands, except EPS Change Jan–Jun 2026 Jan–Jun 2025 Item % % (%) (A) (B) (A-B)/B Net revenue 70,428 100 61,570 100 14 Gross profit 25,745 37 19,563 32 32
Slide 22: Thank You!